Read original release here January 17, 2019 at 7:05 AM EST DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the Phase 1 trial evaluating neoepitopes formulated in the Company’s proprietary DPX delivery platform in patients with ovarian…

Read full article here After receiving surprisingly strong results from its first clinical trials, Halifax-based PhotoDynamic has altered its business strategy to build up more value in the company before contemplating an exit. PhotoDynamic is developing a device that uses natural extracts from a wild Nova Scotia plant to erase heavy plaque buildup on teeth. Last spring, it…

BioNova advocates on behalf of the sector for initiatives that are important to attract investment to the province. learn more about the recommendations we’re presenting to Government on modernizing Equity Tax Credits for Atlantic Canada by clicking on the image below. To add your signature of support for these recommendations CONTACT US

Read original article here   Over the last several years, the topic of mental health has come to the forefront. What was once as a topic veiled in shame and secrecy is not being discussed openly, and for the better. Whether it’s in the workplace, educational institutions, or at alone at home, businesses and startups worldwide are…

See original article here DARTMOUTH, Nova Scotia, Sept. 04, 2018 (GLOBE NEWSWIRE) — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, celebrated its grand opening today of its new facilities in Dartmouth, Nova Scotia. Frederic Ors, IMV’s Chief Executive Officer, and Andrew Sheldon, IMV’s Chairman of the Board, opened today’s event with remarks about the company’s milestones and successes….

See original story here Eight companies have been chosen to compete in this year’s BioInnovation Challenge, a regional health and life sciences business competition hosted by BioNova. The competition will go down on Nov. 7 at BioPort 2018, BioNova’s annual conference for the life-science industry at the Halifax Convention Centre. The BIC is one of the longest running business competitions…

NEWS RELEASE FOR IMMEDIATE RELEASE BioNova Names 2018 BioInnovation Challenge (BIC) Semi-Finalists August 29, 2018 – Halifax, Nova Scotia – Eight (8) semi-finalists have been chosen to compete in the BioInnovation Challenge (BIC), BioNova’s regional health and life sciences business competition, which will be held in Halifax on November 7th during BioPort 2018 at the…

CNW – Adaptiiv Receives FDA 510(k) Clearance to Market 3D Bolus Software – Adaptiiv, an innovative medical technology company announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market 3D Bolus Software, an advanced software solution that enables the creation of customized personal medical devices using 3D printing,…

CHARLOTTETOWN, Prince Edward Island (12/14/2017) – BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a long-term supply agreement with Keryx Biopharmaceuticals, Inc., to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia® tablets, a medicine approved for the treatment of two common complications of chronic kidney disease. BioVectra Inc….

See original story here As it continues to fund young companies, the First Angel Network has developed an investment niche for the biomedical space and is showing an eagerness for repeat investments. FAN, as it is known, has been investing in Atlantic Canadian startups for 12 years, making it the dean of active investment groups….

2015 © Copyright - Bionova